Skip to content
Subscriber Only

Sanofi-Regeneron Drug Lowers Cholesterol Up to 72% in Study

An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc. lowered patients’ so-called bad cholesterol by as much as 72 percent on top of Lipitor in a company-funded study.

The medicine, one in a class of drugs targeting the PCSK9 gene, reduced patients’ average LDL cholesterol levels to as little as 34 milligrams per deciliter after 12 weeks in the mid-stage study, presented today at the American College of Cardiology meeting in Chicago. Less than 100 mg/dL is considered optimal for LDL, according to the Mayo Clinic.